can i switch from retatrutide to tirzepatide vs. Retatrutide: Key Differences Explained switching to retatrutide from tirzepatide

This ensures the treatment plan is safe, targeted, and personalized

View Apple Pay countries and regions

Cardiometabolic Improvements Weight loss was accompanied by clinically meaningful improvements across several cardiovascular risk markers, including reductions in: Waist circumference (mean reduction of approximately 24.1 cm at the highest dose) Non-HDL cholesterol Triglycerides Systolic blood pressure High-sensitivity C-reactive protein (hsCRP) a marker of inflammation These findings are particularly relevant for patients with obesity who also live with cardiometabolic conditions, where systemic risk reduction is as important as the weight loss itself

\n\nIn your clinical practice, how early are you introducing SGLT2 inhibitors into the journey of the non-diabetic chronic kidney disease patient, and how do you manage the concern over the initial drop in glomerular filtration at the start of treatment

Lets say you have a health condition like heart disease and meet certain criteria

We have 20 years of safety data, Shahed says